Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04881019 · ClinicalTrials.gov registry record
PRediction Of Glycemic RESponse Study
A clinical trial of Glycemic Response, sponsored by Scripps Translational Science Institute.
- Active
- Registry status
- 1,070
- Enrollment target
- 1
- Study location
NCT04881019: Active study of Glycemic Response, sponsored by Scripps Translational Science Institute.
NCT04881019 is a study of Glycemic Response that is active but no longer recruiting, run by Scripps Translational Science Institute. The registered enrollment target is 1,070 participants, above the 51-participant average among 4 other Glycemic Response trials with a reported enrollment target (1998% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04881019, a study of Glycemic Response, is active but no longer recruiting, sponsored by Scripps Translational Science Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 1,070 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary intake, activity levels, and continuous glucose values over 10 days, link to clinical events out to 3-years, and use that data along with genomic, microbiome, electronic health record (EHR), and other biomarker data to develop a predictive model of individual glucose responses to nutrient intake in individuals with and without type 2 diabetes.
Primary Outcome
Distinguish differences in individual glycemic response characteristics as measured by the continuous glucose monitor (mg/dl) and macronutrients (carbohydrates, fats, and proteins) in participants with (n = 500) and without type 2 diabetes (n = 500) matched for age, sex, BMI.
Conditions Studied
Interventions
- DEVICE Continuous glucose monitoring
Study Locations (1)
California
- Scripps Research Translational Institute - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,070 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT04881019 still lists
NCT04881019 is an observational study that tracks outcomes without assigning an intervention. Its 1,070 participants enrollment target places it among the larger protocols in the corpus, above the 51-participant average among 4 other Glycemic Response trials with a reported enrollment target (1998% higher).
The record links to 1 condition, with Glycemic Response appearing as the primary indexed condition, and to 1 intervention - of which Continuous glucose monitoring is the first listed.
NCT04881019 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04881019 about?
NCT04881019 is a clinical study titled "PRediction Of Glycemic RESponse Study". The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary intake, activity levels, and continuous glucose values over 10 days, link to clinical events out to 3-years, and use that data along with genomic, microbiome, electronic health record (EHR), and other biomarker da...
What is the current status of trial NCT04881019?
This trial is currently active not recruiting. The enrollment target is 1,070 participants. The study started on 2021-06-08. Estimated completion is 2025-12-31.
What conditions does trial NCT04881019 study?
This clinical trial studies the following conditions: Glycemic Response.
What interventions are being tested in trial NCT04881019?
The interventions under investigation include: Continuous glucose monitoring (DEVICE).
Who is sponsoring clinical trial NCT04881019?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04881019 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glycemic Response
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)
RECRUITING · NA
-
The Impact of Fruit Juice, Fruit Juice With Pomace, or Whole Fruit on Glycemic Response
COMPLETED · NA
-
Effects of Concord Grape Juice Alone on Glycemia, Appetite and Cognitive Function in Healthy Adults
COMPLETED · NA
-
The Breakfast Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI